Navigation Links
GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
Date:2/28/2017

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform.

“The combined power of the Trianni and GigaGen technologies will produce an unprecedented pipeline of fully-human antibodies,” said Dave Johnson, PhD, MBA, CEO of GigaGen. “We are confident that the resulting portfolio will have an enormous impact on the field of immuno-oncology.”

The Trianni Mouse has been engineered with genetic loci that are optimized for the expression of antibodies that are entirely human in their variable domains. Because they retain mouse constant regions in their antibody repertoires, the mice are not immunocompromised, but rather exhibit robust lymphocyte development and immune responses.

GigaGen's highly efficient immune repertoire sequencing and expression platform captures full B-cell repertoires and then builds protein display libraries from the repertoires to rapidly validate binding and function. Using GigaGen's technology, a single mouse produces hundreds or thousands of therapeutic candidates, which are rapidly sequenced and validated for binding affinity.

“We are excited to put The Trianni Mouse into the hands of our partners at GigaGen,” said David Meininger, PhD, MBA, CBO of Trianni. “In prior roles in research and in business development, I evaluated many antibody discovery technologies, and believe that GigaGen and Trianni have transformative technologies that together offer enormous potential to rapidly identify new immuno-oncology treatments.”

About Trianni, Inc.
Trianni is a privately held organization, formed in 2010, with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company is headquartered in San Francisco, CA. For more information about Trianni is available through its corporate website, http://www.trianni.com.

About GigaGen
GigaGen is a biopharmaceutical company developing novel antibody and T-cell therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of the entire immune repertoire, capturing and genetically analyzing B and T-cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies. For more information visit GigaGen.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14086333.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. GigaGen Announces Successful Completion of Technical Goals on Four NIH Grant Projects
2. TRIANNI unterzeichnet eine Lizenzvereinbarung mit Janssen über die Verwendung seiner transgenen Mausplattform
3. TRIANNI Signs Licensing Agreement for Transgenic Mouse Platform Use with Janssen
4. TRIANNI Announces Issuance of Russian Federation Patent
5. Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
6. Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease
7. BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
8. Greater Gift Initiative Announces Partnership with Compass Research
9. SPIE Announces New Fellows of 2017
10. Origin, Arcadia Announce China Biotechnology Collaboration in Corn
11. Pharma and Biotechnology Consulting Firm Announces European Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
(Date:10/6/2017)... Mass. (PRWEB) , ... October 06, 2017 , ... ... female entrepreneurship within the healthcare and technology sector at their fourth annual Conference ... panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage ...
(Date:10/5/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... back to cancer research with a month-long promotion supporting the advancement of breast cancer ... can use promo code PinkRibbon to get 10 percent off their purchase of every ...
(Date:10/5/2017)... ... October 05, 2017 , ... NIH ... of its Nanobind DNA/RNA extraction technology . Nanobind is a novel magnetic ... surface and that can be used for a wide variety of sample preparation ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):